RA0688

antibody from Oursmab

Targeting: SLAMF7 19A, CD319, CRACC, CS1

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0688

Provider

Oursmab

Product name

Elotuzumab (Biosimilar Reference Antibody) (SLAMF7)

Antibody type

Monoclonal

Description

Elotuzumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody approved for the treatment of multiple myeloma. It represents a first-in-class immunostimulatory therapy with a unique dual mechanism of action. First, it directly binds to SLAMF7 on myeloma cells. Second, and critically, it simultaneously binds to Fc gamma receptors (Fc¦ÃR) on natural killer (NK) cells via its Fc portion. This dual engagement specifically activates NK cells and directs their cytotoxic activity against the SLAMF7-positive myeloma cells, primarily through antibody-dependent cellular cytotoxicity (ADCC). Unlike most monoclonal antibodies, elotuzumab does not directly induce apoptosis or block a signaling pathway on the tumor cell itself.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.